Navigation Links
Shorter treatment with hepatitis C drug combination may be more beneficial, study shows
Date:9/14/2011

CINCINNATIUniversity of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medicationa telaprevir-based regimen that is commonly used to treat the illnessfor 24 weeks were cured.

Usually, the treatment is administered for 48 weeks, and these results show that extended treatment is unnecessary, possibly changing the standard of care for hepatitis C patients. Researchers say this could mean better medication adherence as well as the decrease in side effects associated with longer medication use.

"Chronic infection with hepatitis C represents a serious health issue for nearly 200 million people worldwide," says Kenneth Sherman, MD, PhD, a UC Health digestive diseases expert, professor and chair of the division of digestive diseases at the UC College of Medicine and principal investigator of the study. "For many years, standard treatment of the type of hepatitis C most common in the United States required 48 weeks of treatment with two drugs: pegylated interferon and ribavirin. Sustained virologic response (cure) occurred in 40 to 50 percent of patients.

"In this clinical trial, we wanted to determine whether there was a group of patients that could be treated for a shorter period without sacrificing the response rate."

Hepatitis C is a viral disease that leads to inflammation of the liver. It can be spread through exchange of bodily fluids with an infected person.

In the study, 540 patients with hepatitis C who had not previously received treatment were enrolled. Seventy-two percent of all patients who entered the study had sustained viral response.

"The high viral cure rates showed that there was no benefit to extending the therapy to 48 weeks for the majority of people in this trial," Sherman says. "Importantly, patients in this trial had a high likelihood of achieving a cure with 24 weeks of total therapy if they had a rapid response to these regimens by week four. Knowing this may provide important motivation for people to continue therapy."

For this study, all patients received telaprevira protease inhibitor for hepatitis Cevery eight hours, peginterferon alfa-2a every week and ribavirin daily for 12 weeks. Then, telaprevir was stopped, and patients received just peginterferon-ribavirin until week 20.

Patients who had an extended rapid virologic response (undetectable hepatitis C virus RNA levels in their blood at four and 12 weeks) were randomly assigned after the 20th week to receive the pegylated interferon and ribavirin for either four or 28 more weeks. Patients without an extended rapid virologic response, who still had detectable hepatitis C, were automatically assigned to an additional 28 weeks

A total of 35265 percentof patients in the study had an extended rapid virologic response.

Among the patients with an extended rapid virologic response who were randomly assigned to receive the combination, 92 percent in the 24-week group and 88 percent in the 48-week group had a sustained virologic response of hepatitis C infection.

"These results are likely to change treatment standards for patients with hepatitis C and reduce adverse effects of the treatment regimen," adds Sherman.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4553
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. For Some Breast Cancer Patients, Shorter Radiation Works Well
2. CT and MRI scans associated with shorter hospital stays and decreased costs
3. Shorter Hospital Stays May Hinder Heart Failure Patients
4. Shorter Telomere Length Again Linked to Cancer
5. The Longer You Sit, the Shorter Your Life Span: Study
6. Engineering shorter wait times in the ER
7. Study links shorter sleep durations with greater risks of mental distress in young adults
8. Shorter Sleep in Men Ups Risk of Heart Disease: Study
9. New findings on drug tolerance in TB suggest ideas for shorter cures
10. Shorter Hospital Stays, More Readmissions After Hip Replacements
11. Stress and depression are associated with shorter survival in head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology: